~~<i id='720CB8635A'><strike id='720CB8635A'><tt id='720CB8635A'><pre id='720CB8635A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：entertainment 2025-09-28 23:48:57 - browse：1

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： A Q&A with Aletha Maybank, AMA’s chief health equity officer

explore

Wikipedia

entertainment

knowledge

focus

TheProLondietincludesallthecaloriesyou'lleatforfivedays,packagedinasmallwhitebox.UshaLeeMcFarling/ST

WSS

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

The most pressing bird flu mysteries scientists want answered

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Senators tussle over abortion against the backdrop of a presidential campaign

Eli Lilly’s Zepbound improved liver scarring in mid

Anthony Fauci pushes back on GOP claims during Covid hearing

entertainment

focus

explore

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Peter Hotez and the public health issue of online harassment

Why getting cancer drugs just got harder for rural patients

Supreme Court strikes down use of affirmative action

The most pressing bird flu mysteries scientists want answered

23andMe had bad news about my health. I wish a person had delivered it

Eli Lilly’s Zepbound improved liver scarring in mid

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Wikipedia

Pfizer highlights cancer drugs it thinks could reignite investor interest

For pregnant people, addiction treatment shouldn't mean a call to child protective services

How to fix the rural physician shortage in the U.S.

Medicare Advantage's lean provider networks lead CMS complaints

STAT wants to know your pick for a great summer read or listen

ASCO Takeaways: Winners, snoozers, and the art of cancer care

entertainment

knowledge

focus

focus